



# Market Announcement

22 September 2020

---

## Cardiex Limited (ASX: CDX) – Trading Halt

### Description

The securities of Cardiex Limited ('CDX') will be placed in trading halt at the request of CDX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 24 September 2020 or when the announcement is released to the market.

### Issued by

**Corey Lian**

Listings Adviser, Listings Compliance (Sydney)



22 September 2020

Mr Corey Lian

By Email

To: [Corey.Lian@asx.com.au](mailto:Corey.Lian@asx.com.au); [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

---

Dear Sir,

**RE: Request for Trading Halt on Securities of CardieX Limited  
(ASX: CDX)**

Pursuant to Listing Rule 17.1, pending an announcement regarding the Company's imminent signing of a material commercialisation agreement, CDX formally applies for a trading halt to be put in place immediately pre commencement of trade today 22 September 2020.

That trading halt is requested to be in place until commencement of trade 24 September 2020 or when that announcement is released to the market.

CDX is not aware of any reason why the Company's request for a trading halt should not be granted.

This request has been authorised for release by the Board of Directors.

Yours sincerely,

**CARDIEX LIMITED**

A handwritten signature in blue ink, appearing to read "Jarrod White", written over the printed name and title.

**JARROD WHITE  
DIRECTOR**

For more information please contact:

**Investor Relations**

Rod Hinchcliffe

[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)

**Media Relations**

Melissa Hamilton

[melissa.hamilton@mcpartners.com](mailto:melissa.hamilton@mcpartners.com)



## **About CardieX**

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company's ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR.X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).